Skip to Main Content

24-1135 2025 Prior Authorization Changes to Medical Benefit Medications

Date: 10/22/24

Learn which drugs have been added, changed or removed from prior authorization requirements

View the tables below for prior authorization (PA) requirements changes for the Los Angeles County Department of Health Services (LA-DHS) participating physician groups (PPGs). These changes all apply to outpatient pharmaceuticals (submitted under the medical benefit).

Additions, effective January 1, 2025

The following require PA.

Requirement

Code and description

Comments

Anktiva®

J9999, Not otherwise classified, antineoplastic drugs

N/A

BeqvezTM

J3590 Unclassified biologics

N/A

BkemvTM

J1300, Injection, eculizumab, 10 mg

Code currently requires authorization: Soliris®

ImdelltraTM

J3590, Unclassified biologics

N/A

Imlygic®

J9325, Injection, talimogene laherparepvec, per 1 million plaque forming units

Gene therapy

Ketalar®

J3490, Unclassified drugs

N/A

LenmeldyTM

J3590, Unclassified biologics

N/A

Leukine®

J2820, Injection, sargramostim (GM-CSF), 50 mcg

N/A

Tevimbra®

J3490, Unclassified drugs

PD 1 inhibitor

Tyenne®

J3262, Injection, tocilizumab,
1 mg

Code currently requires authorization: Actemra®

 

Changes, effective January 1, 2025

The following are changes to existing PA requirements.

Requirement

Code and description

Comments

Darzalex®

  • J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
  • J9145 Injection, daratumumab, 10 mg

Changed to Darzalex/Darzalex Faspro®

NyvepriaTM

Q5122 Injection, pegfilgrastim-apgf, biosimilar, 0.5 mg)

Changed to preferred

Ziextenzo®

Q5120 Injection, pegfilgrastim-bmez, biosimilar, 0.5 mg)

Changed to nonpreferred

 

Deletions, effective January 1, 2025

The following no longer require PA.

Requirement

Code and description

BCG Intravesical

J9030 BCG live intravesical instillation, 1 mg

Nuzyra®

J0121 Injection, omadacycline, 1 mg

Sandostatin®

J2354 Injection, octreotide, nondepot form for subcutaneous or intravenous
injection, 25 mcg

SensiparTM

J0604 Cinacalcet, oral, 1 mg, (for end-stage renal disease on dialysis)

 

Additional information

Providers are encouraged to access the provider portal for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Medi-Cal Provider Services Center at 800-675-6110. Behavioral health providers can call 844-966-0298.

 

This information applies to Physicians, Participating Physician Groups (PPGs), Hospitals, Ancillary Providers, and Behavioral Health Providers.

For Medi-Cal, this information applies to Los Angeles (LA-DHS).



Last Updated: 10/17/2024